
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39256443
71991
10.1038/s41598-024-71991-2
Article
A systematic review of Bannayan – Riley – Ruvalcaba syndrome
Kapačinskaitė Medeinė medeine.kapac@gmail.com

1
Stratica Natalia 2
Adomaitienė Irina 3
Rascon Jelena 4
Vaišnytė Birutė 15
1 https://ror.org/03nadee84 grid.6441.7 0000 0001 2243 2806 Faculty of Medicine, Vilnius University, M.K. Čiurlionio g. 21, 03101 Vilnius, Lithuania
2 https://ror.org/03hd30t45 grid.411038.f 0000 0001 0685 1605 University of Medicine and Pharmacy “Grigore T. Popa”, Strada Universității 16, 700115 Iași, Romania
3 https://ror.org/03nadee84 grid.6441.7 0000 0001 2243 2806 Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos, Santariskiu 24, 08406 Vilnius, Lithuania
4 https://ror.org/03nadee84 grid.6441.7 0000 0001 2243 2806 Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
5 https://ror.org/03nadee84 grid.6441.7 0000 0001 2243 2806 Center of Vascular and Endovascular Surgery, Vilnius University Hospital Santaros Klinikos, Santariskiu 2, 08406 Vilnius, Lithuania
10 9 2024
10 9 2024
2024
14 211197 10 2023
2 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Bannayan–Riley–Ruvalcaba syndrome (BRRS) is a rare overgrowth condition caused by a pathogenic variant in the phosphatase and tensin homolog (PTEN) gene and belongs to a group of disorders called PTEN hamartoma tumor syndrome (PHTS). The diagnosis is often complicated by great phenotypic diversity. Furthermore, to this date treatment options are limited. Here we performed a systematic review using PubMed, Cochrane, and Scopus databases to identify cases of pediatric patients diagnosed with BRRS and summarized information about the clinical presentation, treatment, and long-term patient care. A total of 83 pediatric patients with BRRS were identified. The most common clinical findings were macrocephaly (77%) and developmental disorders (63%). Surgical interventions were the treatment of choice, described in 19 articles. Patient surveillance was proposed in 15 case reports and mostly aimed at periodic cancer screening. Recognition of BRRS clinical symptoms and early referral to a geneticist is important for better disease control and overall prognosis. As targeted treatment is still lacking, symptom relief and long-term surveillance remain the main management strategies.

Subject terms

Medical research
Genetics research
Paediatric research
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

The phosphatase and tensin homolog (PTEN) gene is a tumor suppressor gene that controls cell proliferation, survival, metabolism, and migration by downregulating the PI3K-AKT-mTOR pathway1 . PTEN pathogenic variants can cause several overgrowth syndromes, together known as PTEN hamartoma tumor syndrome (PHTS). These conditions include Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), Lhermitte-Duclos disease, autism spectrum disorders with macrocephaly, Proteus, Proteus-like and VATER (Vertebral defects, Anal atresia, Tracheo-esophageal fistula with Esophageal atresia, and Radial and Renal dysplasia) syndromes2 . They share common key features, such as multiple hamartomas, developmental anomalies, and a higher risk of cancer. However, phenotypes of PHTS can vary greatly, especially when comparing pediatric and adult patients due to age-related penetrance. We chose to explore the available literature on BRRS in the pediatric cohort. This article aims to raise awareness among clinicians and patients about this rare syndrome to facilitate earlier diagnosis and choose a prompt management strategy.

BRRS is a rare genetic disorder that is mostly diagnosed among children and is typically characterized by the growth of hamartomatous, lipomatous, or vascular tumors, congenital macrocephaly, developmental delay, and pigmented genital macules3. Prenatal overgrowth and musculoskeletal system disorders such as myopathy of proximal muscles and scoliosis are other clinical features commonly found among individuals with BRRS4. PTEN pathogenic variants in BRRS cases usually demonstrate autosomal dominant inheritance; nevertheless, it is estimated that up to 48% of pathogenic variants can be de novo2,5. Patients with BRRS are considered to share the same lifetime risk of cancer as individuals with Cowden syndrome, however, it has not been confirmed by formal studies4. Additionally, they are susceptible to complications related to gastrointestinal polyps and vascular anomalies. Therefore, early diagnosis and consistent surveillance are important3,6.

There is no established standard treatment for PHTS patients; however, a promising therapy with mammalian target of rapamycin (mTOR) inhibitors is currently under research and can be prescribed as an off-label drug2. mTOR inhibitors have been investigated in patients with vascular anomalies when previous treatments were ineffective7. Here, we present a systematic review that was conducted to summarize the clinical features of pediatric patients with BRRS and to discuss potential treatment and long-term surveillance.

Methods

This systematic review was pursued to summarize the clinical features of pediatric patients with BRRS and to discuss potential treatment and long-term surveillance strategies. The systematic review was conducted following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines8. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (registration number: CRD42022370744) before starting the search. The study protocol was approved by Vilnius University Santaros Clinics research committee.

Eligibility criteria

The inclusion criteria were pediatric patients (0-18 years old) diagnosed with BRRS and patients of any age with BRRS who received treatment with sirolimus. We included full-text, free or available observational studies, case series, and case reports from Vilnius University. Editorials, letters, systematic reviews, literature reviews, comments, guidelines, conference abstracts, expert opinions, and non-English articles were excluded.

Literature search

The PubMed, Scopus, and Cochrane collaboration databases were searched using the following keywords and their combinations: Bannayan Riley Ruvalcaba Syndrome, Bannayan Zonana Syndrome, BRRS, BZS, Myhre Riley Smith syndrome, Riley Smith syndrome, Ruvalcaba Myhre syndrome, Ruvalcaba Myhre Smith syndrome, Bannayan Zonana Syndrome, child, children, and adolescent. We also used the truncation technique (*) with the following words to expand the number of results: pediatri*/, infan*/, newbor*/. An additional search adding the keywords sirolimus, rapamycin, rapamycin, AY 22 989, and 2190A was performed to review the relevant literature on sirolimus efficacy in BRRS. The literature selection was not limited by publication date due to the rarity of the syndrome. Automation search tools were used to include open-access journal articles in the English language. The search was conducted by two reviewers (MK and NS) independently.

Study selection and data extraction

Deduplication of found articles was performed with the citation management software EndNote. First, the titles and abstracts were screened for eligibility, followed by a full-text review of the potentially included publications. The extracted data included authorship, publication year, sample size, demographics of cases, status of PTEN pathogenic variant, family history, clinical presentation, treatment, follow-up care, and outcomes. Two reviewers (MK and NS) independently performed the screening of articles and eligible information selection. Chosen publications and extracted data by both team members were compared, and any disagreements were resolved by discussion.

Evaluating the risk of bias

The quality of the included publications was assessed by each reviewer independently using Joanna Briggs Institute's (JBI) Critical Appraisal Checklist for case reports and case series9,10. The following evaluation criteria were established: low risk of bias was attributed to articles with more than 70% “yes” answers; moderate risk for articles with 50% to 69% “yes” answers; and high risk of bias for studies with less than 49% “yes” answers.

Data analyses

This review consists of case reports and case series; therefore, the heterogeneity of study designs and outcomes made statistical analysis not applicable. Henceforth, a descriptive approach and tabulation were selected to present the results and conclusions.

Results

Of the 2600 publications acquired from the search, 55 duplicates and 2475 original articles were excluded following the inclusion/exclusion criteria and automation tools (Figure 1). After the full-text review of the remaining 70 publications, 37 articles were excluded because they did not meet the inclusion criteria or did not contain relevant information. In total, 33 studies were eligible for the review11–43. The methodological quality assessment was performed together with the data extraction (see Supplemental Tables S1 and S2 in Additional File 1).Figure 1 PRISMA flow chart.

Overall, 83 children with BRRS were included in the review. Supplemental Table S3 summarizes the median age and gender of patients, the status of PTEN pathogenic variant, relevant conditions of parents and siblings, management, surveillance, and outcomes. If the report did not provide the information mentioned above, it was marked in the tables as not available (N/A). A 22-year-old patient was included in the review because the case report mostly described his pediatric history35. The majority of patients were males (60/83), and the median age of the entire cohort was 8 years. In addition, most patients had PTEN pathogenic variants (75/83), whereas only approximately half of the studies reported a positive family history (14/33). Treatment mainly comprised surgical removal of lesions (most commonly lipomas, gastrointestinal polyps, and vascular anomalies); a few cases also mentioned thyroidectomies20,35,41,43, and only one study reported the use of rapamycin25.

In 15 reports, follow-up visits were proposed; however, strategies of surveillance were diverse, mostly aiming at cancer screening. Long-term outcomes were reported in only 6 cases11,18,21,25,35,40. In 3 cases, patients did not develop any new symptoms, while 2 reports described the recurrence of lipomas and gastrointestinal polyps.

Macrocephaly was described in almost all case reports (32/33). Pigmented penile macules were described in the majority of male reports (21/28). Lipomas were mentioned in more than half of the cases (18/33), and the second most common lesion was gastrointestinal polyps (16/33). Another frequent finding was vascular abnormalities, namely, hemangiomas (8/33) and AVMs (6/33). Other reported clinical features were as follows: developmental delay or autism spectrum disorders (25/33), skin manifestations (21/33), and thyroid changes (12/33). A complete summary of the phenotypic findings is presented in Table 1. A more detailed list of the clinical characteristics of all included studies is presented in Supplemental Table S4.Table 1 Summary of BRRS clinical findings.

GI gastrointestinal, ASD autism spectrum disorders, DD developmental disorders, M male, F female

Discussion

Clinical phenotypes of BRRS

Studies have shown that approximately 80% to 100% of patients with PHTS have marked macrocephaly (defined as head circumference ≥97th percentile)44. A similar prevalence is seen among children in the reviewed studies. However, height deviations are not associated with the syndrome3.

Mucocutaneous manifestations are present in the majority of PTEN-related syndromes. Most of them appear later in life due to age-related penetrance44. One of the pathognomonic findings in BRRS is lentiginous genital macules which can be present in both males and females45. It is frequently reported in pediatric BRRS cases in patients as young as 1 year old3. Nevertheless, genital speckles can also develop later in adolescence; therefore, the absence of lentigines alone is not a plausible reason to exclude BRRS23. Other skin findings in the reviewed cases were diverse and nonspecific for the syndrome, but the most frequently mentioned were café au lait spots, verrucous papules, and subcutaneous hemangiomas. Vascular and lipomatous lesions are key findings in BRRS. In the included studies, the most common tumors were lipomas, which, although described as benign, can reach a significant volume and act as space-occupying lesions21. Complications of lipomas depend on their localization and can manifest as occlusion, torsion, or cosmetic defects29,46. In addition, testicular lipomas are a rare entity in the general population, occur more often in individuals with PTEN pathogenic variants, and can be a significant indicator for genetic testing13,44.

Other important findings in BRRS are vascular anomalies, namely, AVMs and hemangiomas. Similar to lipomas, vascular lesions can develop in any part of the body. If located in more superficial layers, they can be seen as discoloration of the skin. Most commonly, vascular anomalies cause swelling and pain, but some cases also reported aggressive growth on the extremities, resulting in the loss of function or amputation25,39. Notably, AVMs can occur in the CNS and carry a potential risk of bleeding and complications related to mass effects28,40. A significant prevalence of gastrointestinal polyps in PHTS has been observed in several studies47. Multiple polyps are usually found in both the upper and lower gastrointestinal tracts and have mixed histology, especially with ganglioneuromatous features48. BRRS patients with polyps may present with abdominal pain, hematochezia, anemia, invagination, constipation, or diarrhea22–24,31. Extensive symptom burden or complications such as invagination or blockage may require bowel resection20,23.

Thyroid pathologies are a very common manifestation of PTEN-related syndromes. Up to 75% of patients develop thyroid changes, and approximately one-third will develop thyroid cancer in their lifetime46. While other malignancies tend to appear in adulthood, thyroid carcinoma also occurs among children, with the youngest described patient being 6 years old46. From the included studies, the majority of outlined thyroid changes were nodules; however, 4 studies reported 5 thyroid tumors, of which 3 were carcinomas13,28,35,43.

Developmental delay and autism spectrum disorders (ASD) are also often associated with PHTS. A meta-analysis by Cummings et al. suggests that up to 25% of patients with PTEN pathogenic variants may express characteristics of ASD49. Motor delay is the most common developmental disorder among patients3. Studies included in this systematic review described developmental disorders of different degrees, ranging from normal psychomotor development and mild motor or speech delay to severe intellectual disability. A few cases of ASD and attention deficit disorder have also been reported13,14,22,32,34.

The reviewed studies also outlined less frequent yet notable clinical features of BRRS. Patients are more prone to obesity than the general population due to profound insulin sensitivity50. In addition, some PTEN pathogenic variant carriers can suffer from muscle hypotonia, which is associated with motor delay3. The literature also presents a variety of brain lesions in PHTS patients, mostly located in white matter46. For example, a study by Bhargava et al. assessed brain MRI scans of 7 children with BRRS: almost all patients demonstrated marked macrocephaly, white matter cysts, and abnormal cerebrospinal fluid (CSF) signal intensity (hyperintense on T2 and hypointense on FLAIR)13. Particularly associated with BRRS are musculocutaneous findings such as pectus excavatum, scoliosis, and joint hypermobility51.

It is important to note that both CS and BRRS share the same PTEN alterations and are now considered to be different phenotypic expressions of the same disease52. In addition, there are cases of CS/BRRS overlap families, in which members present with clinical features of either one or both syndromes17,23,42. CS is associated with cancer, and BRRS patients can also develop malignancies later due to CS and BRRS allelism and age-dependent penetrance52.

Diagnostic work-up

There are no internationally established guidelines specifically for the diagnosis of BRRS; nevertheless, the National Comprehensive Cancer Network® (NCCN®) has established diagnostic criteria for PHTS, together with surveillance recommendations for PTEN pathogenic variant carriers44. Patients meeting diagnostic criteria are referred to genetic counseling. Additional critical judgment should be used when applying criteria to the pediatric cohort, since children may express clinical phenotypes different from adults44,46. Pediatric criteria proposed by Tan et al. include the most prevalent PHTS clinical findings in children, namely, macrocephaly, gastrointestinal polyps, neurologic disorders (ASD and developmental delay), dermatologic (lipomas, pigmented genital macules, papillomas), and vascular (AVMs, hemangiomas) features53. German pediatric guidelines updated the Tan et al. criteria by adding positive family history, thyroid changes, and enlarged perivascular spaces in brain MRI46.

Treatment options

Currently, therapy for BRRS is mostly limited to symptom relief, prevention, and eradication of complications. In our reviewed cases, the most frequent intervention was the excision of tumors. Lipomas were the most common masses to be removed. Polypectomies of hamartomatous polyps were also frequent, with two cases of proctocolectomy and subtotal colectomy due to severe symptom burden and recurrence20,23. Thyroid resection and thyroidectomies were described in four cases20,35,41,43. Single cases of scoliosis, seizures, intracranial hypertension, and intracranial tumor treatment were also presented11,19,35,37.

Vascular anomalies are a very common manifestation of BRRS. Sclerotherapy, embolization, and surgery are typical therapy approaches. Nevertheless, these interventions do not always bring satisfactory results due to the complexities of malformations, high frequency of recurrence, and periprocedural morbidity25,39. Therefore, the mTOR inhibitor rapamycin (sirolimus) was proposed as an off-label target agent for treatment of vascular anomalies. PTEN pathogenic variants cause excessive activity of the PI3K-AKT-mTOR pathway, which is responsible for cellular proliferation and angiogenesis induction, leading to the formation of vascular anomalies54. As a result, by downregulating the mTOR pathway, sirolimus could potentially reduce vascular lesions in patients with PHTS.

The first human study of sirolimus for CS investigated its efficacy in 18 adult patients with cutaneous and gastrointestinal lesions55. The trial demonstrated the effectiveness of sirolimus in suppressing mTOR signaling and improving cerebellar function as well as adequate tolerability of the drug. To our knowledge, currently, there are no studies designated for the specific pediatric PHTS group; nevertheless, research has been done among children with vascular anomalies of diverse origins7,56. In retrospective study Hammill et al. 6 children (100%) with treatment-resistant vascular anomalies showed a partial or complete response to sirolimus7. Notably, in a review by Geeurickx et al., 334 cases of pediatric vascular anomalies treated with sirolimus were presented56. It was noticed that the drug efficacy partially depends on the type of malformation. Namely, low-flow vascular anomalies demonstrated the best results. Sirolimus efficacy on fast-flow vascular malformations is yet to be investigated by future clinical trials. In addition, AVMs associated with PTEN pathogenic variants were more responsive to sirolimus monotherapy than isolated AVMs. The systematic literature review by Badawy et al. evaluated sirolimus efficacy in 39 patients with isolated limb overgrowth disorders57. Sirolimus was given as first-line treatment or as an alternative option after previously failed therapies. The reviewed studies were highly variable in terms of sirolimus dosage, length of therapy, and outcome measurement; nevertheless, the results showed a partial response to sirolimus therapy and did not report any case of disease progression. Only one case describing treatment with an mTOR inhibitor was included in our systematic review25. A 6-year-old boy received sirolimus therapy due to resistance to embolization and surgery, persistent pain, and progressive loss of left-hand function. In 6 months, the AVM size decreased, and the patient became pain-free and regained hand mobility. The literature suggests that 6 months is the optimal time to see the maximum response to sirolimus therapy56,58.

In all studies evaluating sirolimus efficacy, adverse reactions were reported, the most common being infections, mucositis, bone marrow suppression, hypercholesterolemia, and elevated liver enzymes7,56,57. Most adverse reactions were not severe and resolved after the dose adjustment7,56. However, awareness of possible drug toxicities and consistent laboratory blood analysis is essential54. Importantly, recurrent symptoms and regrowth of vascular anomalies were observed after discontinuing the treatment56. In addition, it was noticed that sirolimus reduces the volume of vascular anomalies but does not lead to the disappearance of the lesions56,58. Therefore, sirolimus could be used as a polytherapy agent before radical interventions of large complicated vascular anomalies56,58.

It appears that mTOR inhibitors can be an alternative treatment strategy for PHTS patients on individual basis, although current studies are limited by small sample sizes and the absence of randomization. Consequently, more research is required to confirm the potency of sirolimus in treating PTEN-related syndromes.

Long-term surveillance strategies

PHTS is known to be a malignancy-causing syndrome; therefore, the major aspect of follow-up is cancer screening6. Targeted malignancy surveillance in pediatric patients is mostly limited to the thyroid since early-onset changes such as nodules or thyroiditis are common50. Expanded malignancy surveillance and awareness should start in adulthood46,59. The reviewed cases showed similar follow-up strategies and mostly aimed at cancer screening by performing thyroid ultrasound. Dermatological consultation, occult blood tests, and abdominal ultrasound were used in a few cases. As a multisystem disease, PHTS requires a broader follow-up approach, particularly surveillance of nonmalignant manifestations. German pediatric guidelines suggest a screening strategy for children and adolescents which are presented in Supplemental Table S546. They recommend annual physical examinations, including dermatological inspection, neurological and psychomotor assessment, and abdominal ultrasound. Additionally, it is advised to perform thyroid ultrasound after the diagnosis and repeat it periodically if any pathological changes are present. Furthermore, symptom inquiry is important, especially for anemia-related manifestations or gastrointestinal complaints such as abdominal pain, rectal bleeding, obstipation, or diarrhea. Parent education about sun protection, seizures, and concerning symptoms is also encouraged3.

Limitations

The results of our review must be interpreted together with its limitations. Due to the rarity of BRRS, all included studies were case reports and case series. These studies have a high risk of bias. Moreover, study types, heterogeneity, and sometimes incomplete data made generalization impossible. Additionally, we incorporated a number of historical reports that may have interpreted cases with less accuracy than they would with the current knowledge.

Conclusions

Bannayan-Riley-Ruvalcaba syndrome is a rare entity that can manifest in a very broad and diverse spectrum of phenotypes, ranging from mild and subtle symptoms to severe and refractory conditions. Therefore, it is important for clinicians to consider a PTEN pathogenic variant and refer a patient to a geneticist on time. Due to a higher risk of cancer and aggressive growth of hamartomatous anomalies, patients with BRRS require periodic multidisciplinary care that should be individualized to fit every patient’s needs. Currently, surgical interventions are the most common treatment strategy in patients with complicated vascular anomalies; however, the use of mTOR inhibitors could be offered to the patients when other treatment options exhausted. Nevertheless, more research is still needed to fully evaluate their potency in BRRS management.

Supplementary Information

Supplementary Tables.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71991-2.

Author contributions

Conceptualization, J.R., B.V.; acquisition of data, M.K., N.S., I.A.; writing—original draft preparation, M.K.; writing—review and editing, N.S., I.A., J.R., B.V.; supervision, J.R.

Data availability

The dataset supporting the conclusions of this article is included within the article and its additional file.

Competing interests

The authors declare no competing interests.

Ethics Approval and Consent for Publication

Ethics approval was acquired from the Vilnius University Santaros Clinics research committee.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Jelena, Rascon and Birutė, Vaišnytė.
==== Refs
References:

1. Pulido R PTEN: A yin-yang master regulator protein in health and disease Methods San Diego Calif. 2015 77–78 3 10 10.1016/j.ymeth.2015.02.009 25843297
Pulido, R. PTEN: A yin-yang master regulator protein in health and disease. Methods San Diego Calif. 77–78, 3–10 (2015).25843297 10.1016/j.ymeth.2015.02.009
2. Yehia L Keel E Eng C The clinical spectrum of PTEN mutations Annu. Rev. Med. 2020 27 71 103 116 10.1146/annurev-med-052218-125823
Yehia, L., Keel, E. & Eng, C. The clinical spectrum of PTEN mutations. Annu. Rev. Med. 27(71), 103–116 (2020).10.1146/annurev-med-052218-125823
3. Macken WL Tischkowitz M Lachlan KL PTEN hamartoma tumor syndrome in childhood: A review of the clinical literature Am. J. Med. Genet. C Semin. Med. Genet. 2019 181 4 591 610 10.1002/ajmg.c.31743 31609537
Macken, W. L., Tischkowitz, M. & Lachlan, K. L. PTEN hamartoma tumor syndrome in childhood: A review of the clinical literature. Am. J. Med. Genet. C Semin. Med. Genet. 181(4), 591–610 (2019).31609537 10.1002/ajmg.c.31743
4. Gorlin RJ Cohen MM Condon LM Burke BA Bannayan-Riley-Ruvalcaba syndrome Am. J. Med. Genet. 1992 44 3 307 314 10.1002/ajmg.1320440309 1336932
Gorlin, R. J., Cohen, M. M., Condon, L. M. & Burke, B. A. Bannayan-Riley-Ruvalcaba syndrome. Am. J. Med. Genet. 44(3), 307–314 (1992).1336932 10.1002/ajmg.1320440309
5. Mester J Eng C Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome Genet. Med. 2012 14 9 819 822 10.1038/gim.2012.51 22595938
Mester, J. & Eng, C. Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genet. Med. 14(9), 819–822 (2012).22595938 10.1038/gim.2012.51
6. Tan MH Mester JL Ngeow J Rybicki LA Orloff MS Eng C Lifetime cancer risks in individuals with germline PTEN mutations Clin. Cancer Res. 2012 18 2 400 407 10.1158/1078-0432.CCR-11-2283 22252256
Tan, M. H. et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin. Cancer Res. 18(2), 400–407 (2012).22252256 10.1158/1078-0432.CCR-11-2283
7. Hammill AM Wentzel M Gupta A Nelson S Lucky A Elluru R Sirolimus for the treatment of complicated vascular anomalies in children Pediatr. Blood Cancer 2011 57 6 1018 1024 10.1002/pbc.23124 21445948
Hammill, A. M. et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr. Blood Cancer 57(6), 1018–1024 (2011).21445948 10.1002/pbc.23124
8. Page MJ McKenzie JE Bossuyt PM Boutron I Hoffmann TC Mulrow CD The PRISMA 2020 statement: An updated guideline for reporting systematic reviews BMJ 2021 29 372 n71 10.1136/bmj.n71
Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 29(372), n71 (2021).10.1136/bmj.n71
9. Moola S MPF. Chapter 7: Systematic reviews of etiology and risk. In: JBI Manual for Evidence Synthesis [Internet]. JBI; 2020 [cited 2024 Jun 26]. Available from: https://jbi-global-wiki.refined.site/space/MANUAL/355863557/Previous+versions?attachment=/download/attachments/355863557/JBI_Reviewers_Manual_2020June.pdf&type=application/pdf&filename=JBI_Reviewers_Manual_2020June.pdf#page=217
10. Munn Z Barker TH Moola S Tufanaru C Stern C McArthur A Methodological quality of case series studies: An introduction to the JBI critical appraisal tool JBI Database Syst. Rev. Implement Rep. 2019 10.11124/JBISRIR-D-19-00099
Munn, Z. et al. Methodological quality of case series studies: An introduction to the JBI critical appraisal tool. JBI Database Syst. Rev. Implement Rep.10.11124/JBISRIR-D-19-00099 (2019).10.11124/JBISRIR-D-19-00099
11. Ahmed SF Marsh DJ Weremowicz S Morton CC Williams DM Eng C Balanced translocation of 10q and 13q, including the PTENGene, in a boy with a human chorionic gonadotropin-secreting tumor and the Bannayan-riley-Ruvalcaba syndrome J. Clin. Endocrinol. Metab. 1999 84 12 4665 4670 10.1210/jcem.84.12.6178 10599735
Ahmed, S. F. et al. Balanced translocation of 10q and 13q, including the PTENGene, in a boy with a human chorionic gonadotropin-secreting tumor and the Bannayan-riley-Ruvalcaba syndrome. J. Clin. Endocrinol. Metab. 84(12), 4665–4670 (1999).10599735 10.1210/jcem.84.12.6178
12. Arch EM Goodman BK Van Wesep RA Liaw D Clarke K Parsons R Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with cowden disease Am. J. Med. Genet. 1997 71 4 489 493 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B 9286463
Arch, E. M. et al. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with cowden disease. Am. J. Med. Genet. 71(4), 489–493 (1997).9286463 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B
13. Bhargava R Bannayan-Riley-Ruvalcaba syndrome: MRI neuroimaging features in a series of 7 patients Am. J. Neuroradiol. 2014 35 402 10.3174/ajnr.A3680 23907246
Bhargava, R. Bannayan-Riley-Ruvalcaba syndrome: MRI neuroimaging features in a series of 7 patients. Am. J. Neuroradiol. 35, 402 (2014).23907246 10.3174/ajnr.A3680
14. Bishop PR Nowicki MJ Parker PH What syndrome is this? Ruvalcaba-Myhre-Smith syndrome Pediatr. Dermatol. 2000 17 4 319 321 10.1046/j.1525-1470.2000.01787.x 10990586
Bishop, P. R., Nowicki, M. J. & Parker, P. H. What syndrome is this? Ruvalcaba-Myhre-Smith syndrome. Pediatr. Dermatol. 17(4), 319–321 (2000).10990586 10.1046/j.1525-1470.2000.01787.x
15. Blum RR Rahimizadeh A Kardon N Lebwohl M Wei H Genital Lentigines in a 6-year-old boy with a family history of cowden’s disease: Clinical and genetic evidence of the linkage between Bannayan–Riley–Ruvacalba syndrome and Cowden’s disease J. Cutan Med. Surg. 2001 5 3 228 230 11685670
Blum, R. R., Rahimizadeh, A., Kardon, N., Lebwohl, M. & Wei, H. Genital Lentigines in a 6-year-old boy with a family history of cowden’s disease: Clinical and genetic evidence of the linkage between Bannayan–Riley–Ruvacalba syndrome and Cowden’s disease. J. Cutan Med. Surg. 5(3), 228–230 (2001).11685670
16. Buisson P Leclair MD Jacquemont S Podevin G Camby C David A Cutaneous lipoma in children: 5 cases with Bannayan-Riley-Ruvalcaba syndrome J. Pediatr. Surg. 2006 41 9 1601 1603 10.1016/j.jpedsurg.2006.05.013 16952599
Buisson, P. et al. Cutaneous lipoma in children: 5 cases with Bannayan-Riley-Ruvalcaba syndrome. J. Pediatr. Surg. 41(9), 1601–1603 (2006).16952599 10.1016/j.jpedsurg.2006.05.013
17. Celebi JT Tsou HC Chen FF Zhang H Ping XL Lebwohl MG Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN J. Med. Genet. 1999 36 5 360 364 10353779
Celebi, J. T. et al. Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN. J. Med. Genet. 36(5), 360–364 (1999).10353779
18. Erkek E Hizel S Sanlý C Erkek AB Tombakoglu M Bozdogan O Clinical and histopathological findings in Bannayan-Riley-Ruvalcaba syndrome J. Am. Acad. Dermatol. 2005 53 4 639 643 10.1016/j.jaad.2005.06.022 16198785
Erkek, E. et al. Clinical and histopathological findings in Bannayan-Riley-Ruvalcaba syndrome. J. Am. Acad. Dermatol. 53(4), 639–643 (2005).16198785 10.1016/j.jaad.2005.06.022
19. Ghusayni R Sachdev M Gallentine W Mikati MA McDonald MT Hemimegalencephaly with Bannayan-Riley-Ruvalcaba syndrome Epileptic Disord. 2018 20 1 30 34 10.1684/epd.2018.0954 29444762
Ghusayni, R., Sachdev, M., Gallentine, W., Mikati, M. A. & McDonald, M. T. Hemimegalencephaly with Bannayan-Riley-Ruvalcaba syndrome. Epileptic Disord. 20(1), 30–34 (2018).29444762 10.1684/epd.2018.0954
20. Golas MM Auber B Ripperger T Pabst B Schmidt G Morlot M Looking for the hidden mutation: Bannayan–Riley–Ruvalcaba syndrome caused by constitutional and mosaic 10q23 microdeletions involving PTEN and BMPR1A Am. J. Med. Genet. A 2019 179 7 1383 1389 10.1002/ajmg.a.61166 31062505
Golas, M. M. et al. Looking for the hidden mutation: Bannayan–Riley–Ruvalcaba syndrome caused by constitutional and mosaic 10q23 microdeletions involving PTEN and BMPR1A. Am. J. Med. Genet. A 179(7), 1383–1389 (2019).31062505 10.1002/ajmg.a.61166
21. Gontijo GMA Pinto CAL Rogatto SR Cunha IWD Aguiar Junior S Alves CAXDM Bannayan-Riley-Ruvalcaba syndrome with deforming lipomatous hamartomas in infant—Case report An. Bras. Dermatol. 2013 88 6 982 985 10.1590/abd1806-4841.20132730 24474112
Gontijo, G. M. A. et al. Bannayan-Riley-Ruvalcaba syndrome with deforming lipomatous hamartomas in infant—Case report. An. Bras. Dermatol. 88(6), 982–985 (2013).24474112 10.1590/abd1806-4841.20132730
22. Hansen-Kiss E Beinkampen S Adler B Frazier T Prior T Erdman S A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children J. Med. Genet. 2017 54 7 471 478 10.1136/jmedgenet-2016-104484 28526761
Hansen-Kiss, E. et al. A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children. J. Med. Genet. 54(7), 471–478 (2017).28526761 10.1136/jmedgenet-2016-104484
23. Hendriks YMC Verhallen JTCM Van Der Smagt JJ Kant SG Hilhorst Y Hoefsloot L Bannayan-Riley-Ruvalcaba syndrome: Further delineation of the phenotype and management of PTEN mutation-positive cases Fam. Cancer 2003 2 2 79 85 10.1023/A:1025713815924 14574156
Hendriks, Y. M. C. et al. Bannayan-Riley-Ruvalcaba syndrome: Further delineation of the phenotype and management of PTEN mutation-positive cases. Fam. Cancer 2(2), 79–85 (2003).14574156 10.1023/A:1025713815924
24. Hızarcıoğlu-Gülşen H Kılıç E Dominguez-Garrido E Aydemir Y Utine GE Saltık-Temizel İN Polyposis deserves a perfect physical examination for final diagnosis: Bannayan-Riley-Ruvalcaba syndrome Turk. J. Pediatr. 2017 59 1 80 83 10.24953/turkjped.2017.01.014 29168369
Hızarcıoğlu-Gülşen, H. et al. Polyposis deserves a perfect physical examination for final diagnosis: Bannayan-Riley-Ruvalcaba syndrome. Turk. J. Pediatr. 59(1), 80–83 (2017).29168369 10.24953/turkjped.2017.01.014
25. Iacobas I Burrows PE Adams DM Sutton VR Hollier LH Chintagumpala MM Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation Pediatr. Blood Cancer 2011 57 2 321 323 10.1002/pbc.23098 21360661
Iacobas, I. et al. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr. Blood Cancer 57(2), 321–323 (2011).21360661 10.1002/pbc.23098
26. Iskandarli M Yaman B Aslan A A case of B annayan– R iley– R uvalcaba syndrome. A new clinical finding and brief review Int. J. Dermatol. 2016 55 9 1040 1043 10.1111/ijd.13013 26228616
Iskandarli, M., Yaman, B. & Aslan, A. A case of B annayan– R iley– R uvalcaba syndrome. A new clinical finding and brief review. Int. J. Dermatol. 55(9), 1040–1043 (2016).26228616 10.1111/ijd.13013
27. Israel J Lessick M Szego K Wong P Translocation 19;Y in a child with Bannayan-Zonana phenotype J. Med. Genet. 1991 28 6 427 428 10.1136/jmg.28.6.427 1870104
Israel, J., Lessick, M., Szego, K. & Wong, P. Translocation 19;Y in a child with Bannayan-Zonana phenotype. J. Med. Genet. 28(6), 427–428 (1991).1870104 10.1136/jmg.28.6.427
28. Kurek KC Howard E Tennant LB Upton J Alomari AI Burrows PE PTEN hamartoma of soft tissue: A distinctive lesion in PTEN syndromes Am. J. Surg. Pathol. 2012 36 5 671 687 10.1097/PAS.0b013e31824dd86c 22446940
Kurek, K. C. et al. PTEN hamartoma of soft tissue: A distinctive lesion in PTEN syndromes. Am. J. Surg. Pathol. 36(5), 671–687 (2012).22446940 10.1097/PAS.0b013e31824dd86c
29. Laguna BA Iyer RS Rudzinski ER Roybal JL Stanescu AL Torsion of a giant mesocolic lipoma in a child with Bannayan-Riley-Ruvalcaba syndrome Pediatr. Radiol. 2015 45 3 449 452 10.1007/s00247-014-3083-0 25008800
Laguna, B. A., Iyer, R. S., Rudzinski, E. R., Roybal, J. L. & Stanescu, A. L. Torsion of a giant mesocolic lipoma in a child with Bannayan-Riley-Ruvalcaba syndrome. Pediatr. Radiol. 45(3), 449–452 (2015).25008800 10.1007/s00247-014-3083-0
30. Longy M Coulon V Duboue B David A Larregue M Eng C Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype J. Med. Genet. 1998 35 11 886 889 10.1136/jmg.35.11.886 9832032
Longy, M. et al. Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype. J. Med. Genet. 35(11), 886–889 (1998).9832032 10.1136/jmg.35.11.886
31. Lowichik A White FV Timmons CF Weinberg AG Gunasekaran TS Nathan K Bannayan-Riley-Ruvalcaba syndrome: Spectrum of intestinal pathology including juvenile polyps Pediatr. Dev. Pathol. 2000 3 2 155 161 10.1007/s100240050019 10679034
Lowichik, A. et al. Bannayan-Riley-Ruvalcaba syndrome: Spectrum of intestinal pathology including juvenile polyps. Pediatr. Dev. Pathol. 3(2), 155–161 (2000).10679034 10.1007/s100240050019
32. Lynch NE Lynch SA McMenamin J Webb D Bannayan-Riley-Ruvalcaba syndrome: A cause of extreme macrocephaly and neurodevelopmental delay Arch. Dis. Child. 2009 94 7 553 554 10.1136/adc.2008.155663 19321504
Lynch, N. E., Lynch, S. A., McMenamin, J. & Webb, D. Bannayan-Riley-Ruvalcaba syndrome: A cause of extreme macrocephaly and neurodevelopmental delay. Arch. Dis. Child. 94(7), 553–554 (2009).19321504 10.1136/adc.2008.155663
33. Niklinska EB Lyons EM Hicks A Zwerner JP Albers SE Bannayan-Riley-Ruvalcaba syndrome with gingival hyperpigmentation and facial papules Pediatr. Dermatol. 2021 38 5 1351 1353 10.1111/pde.14691 34259361
Niklinska, E. B., Lyons, E. M., Hicks, A., Zwerner, J. P. & Albers, S. E. Bannayan-Riley-Ruvalcaba syndrome with gingival hyperpigmentation and facial papules. Pediatr. Dermatol. 38(5), 1351–1353 (2021).34259361 10.1111/pde.14691
34. O’Rourke DJ Twomey E Lynch SA King MD Cortical dysplasia associated with the PTEN mutation in Bannayan Riley Ruvalcaba syndrome: A rare finding Clin. Dysmorphol. 2012 21 2 91 92 10.1097/MCD.0b013e328351639d 22327138
O’Rourke, D. J., Twomey, E., Lynch, S. A. & King, M. D. Cortical dysplasia associated with the PTEN mutation in Bannayan Riley Ruvalcaba syndrome: A rare finding. Clin. Dysmorphol. 21(2), 91–92 (2012).22327138 10.1097/MCD.0b013e328351639d
35. Valentina P Alessandro M Francesca F Gerdi T Arianna S Cristina M Thyroid involvement in two patients with Bannayan-Riley-Ruvalcaba syndrome J. Clin. Res. Pediatr. Endocrinol. 2013 5 4 261 265 10.4274/Jcrpe.984 24379037
Valentina, P. et al. Thyroid involvement in two patients with Bannayan-Riley-Ruvalcaba syndrome. J. Clin. Res. Pediatr. Endocrinol. 5(4), 261–265 (2013).24379037 10.4274/Jcrpe.984
36. Piccione M Fragapane T Antona V Giachino D Cupido F Corsello G PTEN hamartoma tumor syndromes in childhood: Description of two cases and a proposal for follow-up protocol Am. J. Med. Genet. A 2013 161 11 2902 2908 10.1002/ajmg.a.36266
Piccione, M. et al. PTEN hamartoma tumor syndromes in childhood: Description of two cases and a proposal for follow-up protocol. Am. J. Med. Genet. A 161(11), 2902–2908 (2013).10.1002/ajmg.a.36266
37. Prat D Ben Bassat Mizrachi I Vishnevskia-Dai V Intermediate uveitis in a child with phosphatase and tensin homolog gene mutation and Bannayan-Riley-Ruvalcaba syndrome BMJ Case Rep. 2019 10.1136/bcr-2017-224079 31603075
Prat, D., Ben Bassat Mizrachi, I. & Vishnevskia-Dai, V. Intermediate uveitis in a child with phosphatase and tensin homolog gene mutation and Bannayan-Riley-Ruvalcaba syndrome. BMJ Case Rep.10.1136/bcr-2017-224079 (2019).31603075 10.1136/bcr-2017-224079
38. Schwab JG Pena L Waggoner D Pytel P Two children with macrocephaly, developmental delay, and PTEN mutation Clin. Pediatr. (Phila) 2009 48 1 89 92 10.1177/0009922808321679 18626099
Schwab, J. G., Pena, L., Waggoner, D. & Pytel, P. Two children with macrocephaly, developmental delay, and PTEN mutation. Clin. Pediatr. (Phila) 48(1), 89–92 (2009).18626099 10.1177/0009922808321679
39. Soysal Y Acun T Lourenço C Marques W Yakıcıer M Muscle Hemangiomatosis presenting as a severe feature in a patient with the Pten mutation: Expanding the phenotype of vascular malformations in Bannayan-Riley-ruvalcaba syndrome Balk. J. Med. Genet. 2012 15 1 45 50 10.2478/v10034-012-0007-x
Soysal, Y., Acun, T., Lourenço, C., Marques, W. & Yakıcıer, M. Muscle Hemangiomatosis presenting as a severe feature in a patient with the Pten mutation: Expanding the phenotype of vascular malformations in Bannayan-Riley-ruvalcaba syndrome. Balk. J. Med. Genet. 15(1), 45–50 (2012).10.2478/v10034-012-0007-x
40. Srinivasa RN Burrows PE Dural arteriovenous malformation in a child with Bannayan-Riley-Ruvalcaba syndrome AJNR Am. J. Neuroradiol. 2006 27 9 1927 1929 17032868
Srinivasa, R. N. & Burrows, P. E. Dural arteriovenous malformation in a child with Bannayan-Riley-Ruvalcaba syndrome. AJNR Am. J. Neuroradiol. 27(9), 1927–1929 (2006).17032868
41. Vincenzi G Petralia IT Abbate M Tarantola G Meroni SLC Maggiore R Case report—Multinodular goiter in a patient with CONGENITAL HYPOTHYRoidism and Bannayan-Riley-Ruvalcaba syndrome: The possible synergic role of TPO and PTEN mutation Front. Endocrinol. 2023 8 14 1205785 10.3389/fendo.2023.1205785
Vincenzi, G. et al. Case report—Multinodular goiter in a patient with CONGENITAL HYPOTHYRoidism and Bannayan-Riley-Ruvalcaba syndrome: The possible synergic role of TPO and PTEN mutation. Front. Endocrinol. 8(14), 1205785 (2023).10.3389/fendo.2023.1205785
42. Wanner M Elebi JT Peacocke M Identification of a PTEN mutation in a family with Cowden syndrome and Bannayan-Zonana syndrome J. Am. Acad. Dermatol. 2001 44 2 183 187 10.1067/mjd.2001.110390 11174374
Wanner, M., Elebi, J. T. & Peacocke, M. Identification of a PTEN mutation in a family with Cowden syndrome and Bannayan-Zonana syndrome. J. Am. Acad. Dermatol. 44(2), 183–187 (2001).11174374 10.1067/mjd.2001.110390
43. Zambrano E Holm I Glickman J Huang S Perez-Atayde A Kozakewich HPW Abnormal distribution and hyperplasia of thyroid C-cells in PTEN-associated tumor syndromes Endocr. Pathol. 2004 15 1 55 64 10.1385/EP:15:1:55 15067177
Zambrano, E. et al. Abnormal distribution and hyperplasia of thyroid C-cells in PTEN-associated tumor syndromes. Endocr. Pathol. 15(1), 55–64 (2004).15067177 10.1385/EP:15:1:55
44. Pilarski R Burt R Kohlman W Pho L Shannon KM Swisher E Cowden Syndrome and the PTEN hamartoma tumor syndrome: Systematic review and revised diagnostic criteria JNCI J. Natl. Cancer Inst. 2013 105 21 1607 1616 10.1093/jnci/djt277 24136893
Pilarski, R. et al. Cowden Syndrome and the PTEN hamartoma tumor syndrome: Systematic review and revised diagnostic criteria. JNCI J. Natl. Cancer Inst. 105(21), 1607–1616 (2013).24136893 10.1093/jnci/djt277
45. Pilarski R PTEN hamartoma Tumor syndrome: A clinical overview Cancers 2019 11 6 844 10.3390/cancers11060844 31216739
Pilarski, R. PTEN hamartoma Tumor syndrome: A clinical overview. Cancers 11(6), 844 (2019).31216739 10.3390/cancers11060844
46. Plamper M Gohlke B Woelfle J PTEN hamartoma tumor syndrome in childhood and adolescence—a comprehensive review and presentation of the German pediatric guideline Mol. Cell. Pediatr. 2022 9 1 3 10.1186/s40348-022-00135-1 35187600
Plamper, M., Gohlke, B. & Woelfle, J. PTEN hamartoma tumor syndrome in childhood and adolescence—a comprehensive review and presentation of the German pediatric guideline. Mol. Cell. Pediatr. 9(1), 3 (2022).35187600 10.1186/s40348-022-00135-1
47. Stanich PP Colonic manifestations of PTEN hamartoma tumor syndrome: Case series and systematic review World J. Gastroenterol. 2014 20 7 1833 10.3748/wjg.v20.i7.1833 24587660
Stanich, P. P. Colonic manifestations of PTEN hamartoma tumor syndrome: Case series and systematic review. World J. Gastroenterol. 20(7), 1833 (2014).24587660 10.3748/wjg.v20.i7.1833
48. D’Ermo G Genuardi M Gastrointestinal manifestations in PTEN hamartoma tumor syndrome Best Pract. Res. Clin. Gastroenterol. 2022 58–59 101792 10.1016/j.bpg.2022.101792 35988965
D’Ermo, G. & Genuardi, M. Gastrointestinal manifestations in PTEN hamartoma tumor syndrome. Best Pract. Res. Clin. Gastroenterol. 58–59, 101792 (2022).35988965 10.1016/j.bpg.2022.101792
49. Cummings K Watkins A Jones C Dias R Welham A Behavioural and psychological features of PTEN mutations: a systematic review of the literature and meta-analysis of the prevalence of autism spectrum disorder characteristics J Neurodev Disord. 2022 14 1 1 10.1186/s11689-021-09406-w 34983360
Cummings, K., Watkins, A., Jones, C., Dias, R. & Welham, A. Behavioural and psychological features of PTEN mutations: a systematic review of the literature and meta-analysis of the prevalence of autism spectrum disorder characteristics. J Neurodev Disord. 14(1), 1 (2022).34983360 10.1186/s11689-021-09406-w
50. Ngeow J Sesock K Eng C Clinical implications for germline PTEN spectrum disorders Endocrinol. Metab. Clin. North Am. 2017 46 2 503 517 10.1016/j.ecl.2017.01.013 28476234
Ngeow, J., Sesock, K. & Eng, C. Clinical implications for germline PTEN spectrum disorders. Endocrinol. Metab. Clin. North Am. 46(2), 503–517 (2017).28476234 10.1016/j.ecl.2017.01.013
51. Hobert JA Eng C PTEN hamartoma tumor syndrome: An overview Genet. Med. 2009 11 10 687 694 10.1097/GIM.0b013e3181ac9aea 19668082
Hobert, J. A. & Eng, C. PTEN hamartoma tumor syndrome: An overview. Genet. Med. 11(10), 687–694 (2009).19668082 10.1097/GIM.0b013e3181ac9aea
52. Blumenthal GM Dennis PA PTEN hamartoma tumor syndromes Eur. J. Hum. Genet. 2008 16 11 1289 1300 10.1038/ejhg.2008.162 18781191
Blumenthal, G. M. & Dennis, P. A. PTEN hamartoma tumor syndromes. Eur. J. Hum. Genet. 16(11), 1289–1300 (2008).18781191 10.1038/ejhg.2008.162
53. Tan MH Mester J Peterson C Yang Y Chen JL Rybicki LA A clinical scoring system for selection of patients for PTEN Mutation testing is proposed on the basis of a prospective study of 3042 probands Am. J. Hum. Genet. 2011 88 1 42 56 10.1016/j.ajhg.2010.11.013 21194675
Tan, M. H. et al. A clinical scoring system for selection of patients for PTEN Mutation testing is proposed on the basis of a prospective study of 3042 probands. Am. J. Hum. Genet. 88(1), 42–56 (2011).21194675 10.1016/j.ajhg.2010.11.013
54. Adams DM Ricci KW Vascular anomalies Hematol. Oncol. Clin. North Am. 2019 33 3 455 470 10.1016/j.hoc.2019.01.011 31030813
Adams, D. M. & Ricci, K. W. Vascular anomalies. Hematol. Oncol. Clin. North Am. 33(3), 455–470 (2019).31030813 10.1016/j.hoc.2019.01.011
55. Komiya T Blumenthal GM DeChowdhury R Fioravanti S Ballas MS Morris J A pilot study of Sirolimus in subjects with cowden syndrome or other syndromes characterized by germline mutations in PTEN Oncologist 2019 24 12 1510 e1265 10.1634/theoncologist.2019-0514 31350329
Komiya, T. et al. A pilot study of Sirolimus in subjects with cowden syndrome or other syndromes characterized by germline mutations in PTEN. Oncologist 24(12), 1510-e1265 (2019).31350329 10.1634/theoncologist.2019-0514
56. Geeurickx M Labarque V A narrative review of the role of sirolimus in the treatment of congenital vascular malformations J. Vasc. Surg. Venous Lymphat. Disord. 2021 9 5 1321 1333 10.1016/j.jvsv.2021.03.001 33737259
Geeurickx, M. & Labarque, V. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations. J. Vasc. Surg. Venous Lymphat. Disord. 9(5), 1321–1333 (2021).33737259 10.1016/j.jvsv.2021.03.001
57. Badawy M Ma Y Baldrighi C Oestreich K Jester A Efficacy of mTOR inhibitors (sirolimus) in isolated limb overgrowth: A systematic review J. Hand Surg. Eur. 2022 47 7 698 704 10.1177/17531934211073866
Badawy, M., Ma, Y., Baldrighi, C., Oestreich, K. & Jester, A. Efficacy of mTOR inhibitors (sirolimus) in isolated limb overgrowth: A systematic review. J. Hand Surg. Eur. 47(7), 698–704 (2022).10.1177/17531934211073866
58. Seront E Van Damme A Boon LM Vikkula M Rapamycin and treatment of venous malformations Curr. Opin. Hematol. 2019 26 3 185 192 10.1097/MOH.0000000000000498 30855337
Seront, E., Van Damme, A., Boon, L. M. & Vikkula, M. Rapamycin and treatment of venous malformations. Curr. Opin. Hematol. 26(3), 185–192 (2019).30855337 10.1097/MOH.0000000000000498
59. Tischkowitz M Cancer surveillance guideline for individuals with pten hamartoma tumour syndrome Eur. J. Hum. Genet. 2020 28 10 1387 1393 10.1038/s41431-020-0651-7 32533092
Tischkowitz, M. et al. Cancer surveillance guideline for individuals with pten hamartoma tumour syndrome. Eur. J. Hum. Genet. 28(10), 1387–1393 (2020).32533092 10.1038/s41431-020-0651-7
